Treatment of chronic inflammatory demyelinating polyneuropathy

References

• McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 110,1617–1630 (1987).
   Google Scholar
• Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Aiumlogy48, 321–328 (1997).
   Google Scholar
• Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 24,311–324 (2001).
   PubMed Web of Science ®Google Scholar
• Rotta FT, Sussman AT, Bradley WG, Ram AD, Sharma KR, Shebert RE The spectrum of chronic inflammatory demyelinating polyneuropathy. j Neural. Sri. 173,129–139 (2000).
   PubMed Web of Science ®Google Scholar
• Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 118,359–368 (1995).
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo. Clin. Proc. 50,621-637 (1975). Established CIDP as a definable disease and served as the catalyst for subsequent study.
   Google Scholar
• Albers JVV, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies; clinical and electrodiagnostic features. Muscle Nerve 12, 435–451 (1989).
   PubMed Web of Science ®Google Scholar
• Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology41, 617–618 (1991).
   Google Scholar
• Nicolas G, Maisonobe T, Le Forestier N, Leger JM, Bouche P Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 25, 26–30 (2002).
   PubMed Web of Science ®Google Scholar
• Sharma KR, Cross J, Farronay O, Ayyar DR, Shebert RT, Bradley WG. 28 Immunopharmacology. In: Basic and (1998). Demyelinating neuropathy in diabetes mellitus. Arrh. Neural. 59, 758–765 (2002).
   Google Scholar
• Sharma KR, Cross J, Ayyar DR, Martinez- Arizala A, Bradley WG. Diabetic demyelinating polyneuropathy responsive to iv. immunoglobulin therapy. Arch. Neural. 59,751–757 (2002).
   Google Scholar
• Gorson KC, Ropper AH, Adelman LS, Weinberg DH. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 23,37–43 (2000).
   PubMed Web of Science ®Google Scholar
• Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology43, 2202–2209 (1993).
   PubMed Web of Science ®Google Scholar
• Notermans NC, Franssen H, Eurelings M, Van der Graaf Y, Wokke JH. Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy. Muscle Nerve 23,73–79 (2000).
   Google Scholar
• Dyck PJ, O'Brien PC, Oviatt KF eta]. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann. Neural. 11, 136–141 (1982).
   Google Scholar
• •Established the efficacy of corticosteroids in the treatment of CIDP
   Google Scholar
• Hughes R, Bensa S, Willison H eta]. Randomized controlled trial of iv. immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neural. 50, 195–201 (2001).
   Google Scholar
• Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Arch. Neural. 46,878–884 (1989).
   PubMed Web of Science ®Google Scholar
• Molenaar DS, van Doom PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J. Neural. Neurosurg. fiych. 62,388–390 (1997).
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. CD002062 (2001).
   Google Scholar
• Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment? Am. J. Med. 80,925–929 (1986).
   Google Scholar
• Pecora PG, Kaplan B. Corticosteroids and ulcers: is there an association? Ann. Pharm. 30,870–872 (1996).
   Google Scholar
• Olbricht T, Benker G. Glucocorticoid- induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases. J. Intern. Med. 234,237–244 (1993).
   PubMed Web of Science ®Google Scholar
• Hart SR, Green B. Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgraci Med. 78,242–243 (2002).
   Google Scholar
• Mendell JR, Barohn RJ, Freimer ML eta]. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology56, 445–449 (2001).
   Google Scholar
• Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119,1067–1077 (1996).
   Google Scholar
• •A randomized, double-blind study that established the efficacy of IVIg as initial therapy among patients with CIDP.
   Google Scholar
• Choudhary PP, Hughes RA. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or iv. immunoglobulin. QJM 88,493–502 (1995).
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22,1479–1497 (1999).
   PubMed Web of Science ®Google Scholar
• •Overview of the mechanism of action and adverse effects of IVIg.
   Google Scholar
• Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann. Neural. 51,673–680 (2002).
   PubMed Web of Science ®Google Scholar
• van Doom PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High dose iv. immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neumlogy40, 209–212 (1990).
   Google Scholar
• Berger AR, Herskovitz S, Scelsa S. The restoration of Mg efficacy by plasma exchange in CIDP Neurology45, 1628–1629 (1995).
   Google Scholar
• Ahsan N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy. Nephro111,157–161 (1998).
   Google Scholar
• Ellie E, Combe C, Ferrer X. High dose iv. immune globulin and acute renal failure. N. Engl. Med 327,1032–1033 (1992).
   Google Scholar
• Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high dose iv. immunoglobulin therapy: frequency and risk factors. Ann. Intern Med. 121,259-262 (1994).
   Google Scholar
• Donofrio PD, Tandan R, Albers JW. Plasma exchange in chronic inflammatory demyelinating polyradiculopathy. Muscle Nerve 8,321–327 (1985).
   Google Scholar
• Pollard JD, McLeod JG, Gatenby P, Kronenberg H. Prediction of response to plasma exchange in chronic relapsing polyneuropathy. A clinico-pathological correlation. J. Neural. Sc]. 58,269–287 (1983).
   PubMed Web of Science ®Google Scholar
• Gross ML, Thomas PK. The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. J. Neural. Sc]. 52, 69–78 (1981).
   Google Scholar
• Hahn AF, Bolton CF, Pillay N eta]. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119, 1055–1066 (1996).
   Google Scholar
• •A double-blind, sham-controlled, cross-over study of PE in patients with CIDP that showed the importance of concurrent imrnunosuppression in association with PE.
   Google Scholar
• Dyck PJ, Daube J, O'Brien P, Pineda A. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl. Med. 314,461–465 (1986).
   Google Scholar
• •Controlled study that showed the efficacy of PE in patients with CIDP.
   Google Scholar
• Assessment of plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology47,840–843 (1996).
   Google Scholar
• The Guillain-Barré syndrome study group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology35, 1096–1104 (1985).
   PubMed Web of Science ®Google Scholar
• Bromberg MB, Feldman EL, Jaradeh S, Albers JW. Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy. j Clin. Epidemiology 45, 47–52 (1992).
   Google Scholar
• Kumazawa K, Sobue G, Yamamoto K etal Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy; different beneficial effects and their correlation to the clinical features. Int. Medicine 34,537–541 (1995).
   Google Scholar
• Feasby TE, Hahn AF, Brown WE Long- term plasmapheresis in chronic progressive demyelinating polyneuropathy (abstr). Ann. Neural. 14,122 (1983).
   Google Scholar
• Thornton CA, Griggs RC. Plasma exchange and iv. immunoglobulin treatment of neuromuscular disease. Ann. Neuml 35, 260–268 (1994).
   Google Scholar
• Dwyer JM. Manipulating the immune system with immune globulin. N Engl. Med. 326,107–116 (1992).
   PubMed Web of Science ®Google Scholar
• Rudnicki S, Vriesendorp F, Koski CL, Mayer RE Electrophysiologic studies in the Guillain-Barré syndrome: effects of plasma exchange and antibody rebound. Muscle Nerve 15,57–62 (1992).
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunal Rev 136, 5–28 (1993).
   PubMed Web of Science ®Google Scholar
• Gray DW. Mycophenolate mofetil for transplantation: new drug, old problems? Lancet 346,390 (1995).
   Google Scholar
• Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60,225–232 (1995).
   PubMed Web of Science ®Google Scholar
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Co-operative Study Group. Lancet 345, 1321–1325 (1995).
   Google Scholar
• Kobashigawa J, Miller L, Renlund D eta]. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. 7iansp/antation 66,507–515 (1998).
   Google Scholar
• Wiesner R, Rabkin J, Klintmalm G etal. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporin and corticosteroids in primary liver transplant recipients. Liver Transplant. 7,442–450 (2001).
   Google Scholar
• Stephan A, Masri MA, Barbari A, Kamel G, Karam A, Kilani H. Therapeutic drug level monitoring for mycophenolate mofetil: is it justified? 7ians. Proc. 33,2778–2779 (2001).
   Google Scholar
• Badid C, Desmouliere A, Laville M. Mycophenolate mofetil: implications for the treatment of glomerular disease. Nephml. Dial. Transplant. 16,1752-1756 (2001).
   Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology47,85–118 (2000).
   PubMed Web of Science ®Google Scholar
• Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J. A117. Soc. Nephrol 10,1965-1971 (1999).
   Google Scholar
• Briggs WA, Choi MJ, Scheel PJ Jr. Follow- up on mycophenolate treatment of glomerular disease. Am. J. Rid. Dis. 31, 898–899 (1998).
   Google Scholar
• Dooley MA, Cosio FG, Nachman PH etal Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J. Am. Soc. Nephrol 10,833–839 (1999).
   PubMed Web of Science ®Google Scholar
• Schneider C, Gold R, Schafers M, Toyka Ky. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 25,286–288 (2002).
   PubMed Web of Science ®Google Scholar
• Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. Neural Sci. 185,119–122 (2001).
   Google Scholar
• Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology56, 94–96 (2001).
   PubMed Web of Science ®Google Scholar
• •Report on the use of MMF in the treatment of neuromuscular diseases.
   Google Scholar
• Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy and safety. jAm Acad. Dermatol 17,962–971 (1987).
   PubMed Web of Science ®Google Scholar
• Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug- Sal 24, 645–663 (2001).
   PubMed Web of Science ®Google Scholar
• Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. 77rer. Drug Monit. 23,305-315 (2001).
   Google Scholar
• Ho S, Clipstone N, Timmermann L eta]. The mechanism of action of cyclosporin A and FK506. Clin. Immunal 80, S40—S45 (1996).
   Google Scholar
• Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporin and methotrexate. Am. J. Gastroent. 91,423-433 (1996).
   Google Scholar
• Sandborn WJ. Cyclosporin therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology109,1001–1003 (1995).
   Google Scholar
• Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21, 454–460 (1998).
   PubMed Web of Science ®Google Scholar
• •Details the efficacy of CsA in the treatment of a relatively large number of patients with CIDP.
   Google Scholar
• Mahattanakul W, Crawford TO, Griffin JVV, Goldstein JM, Cornblath DR. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J. Neural. Neurosurg. Psych. 60, 185–187 (1996).
   Google Scholar
• Schlitt HJ, Barkmann A, Boker KH eta]. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 357, 587–591 (2001).
   PubMed Web of Science ®Google Scholar
• Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side effects of ciclosporine-A and tacrolimus. Clinical Aiphml. 49,356–363 (1998).
   Google Scholar
• Feutren G, Mihatsch MJ. Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporin in Autoimmune Diseases. N Engl. J Med. 326,1654–1660 (1992).
   Google Scholar
• Bechstein WO. Neurotoxicity of cakineurin inhibitors: impact and clinical management. Transplant Int. 13,313–326 (2000).
   PubMed Web of Science ®Google Scholar
• Cush JJ, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J. Rheumatol 26,1176–1186 (1999).
   PubMed Web of Science ®Google Scholar
• Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51,1735–1738 (1998).
   PubMed Web of Science ®Google Scholar
• Brannagan TH III, Pradhan A, Heiman- Patterson T et al High dose cyclophosphamide without stem cell rescue for refractory CIDP Neurology58, 1856–1858 (2002).
   Google Scholar
• Gorson KC, Chaudhry V. Chronic inflammatory demyelinating polyeneuropathy. CU17: Treat. Options Neural 1,251–261 (1999).
   Google Scholar
• Dyck PJ, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neumlogy 35,1173–1176 (1985).
   PubMed Web of Science ®Google Scholar
• Van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. CD001797 (2002).
   Google Scholar
• Bouchard C, Lacroix C, Plante V eta]. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52,498–503 (1999).
   Google Scholar
• Simmons Z, Albers JW. Chronic inflammatory demyelinating polyradiculopathy and related disorders. In: Neuromuscular Disorclers in Clinical Practice. Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, (Eds). Butterworth-Heinemann, MA, USA 567–588 (2002).
   Google Scholar
• •A review of CIDP: clinical presentation, evaluation and diagnosis, treatment and management.
   Google Scholar